Physician profile
Mark S Springer
NPI 1942289509
$1,512.31
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $523.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $596.03 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $208.30 | 2019-2020 | |
| Lilly USA, LLC | $143.93 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $124.77 | 2020 | |
| Novo Nordisk INC | $100.28 | 2019-2020 | |
| Amgen INC. | $87.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.77 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $52.40 | 2019-2020 | |
| Biofire Diagnostics, LLC | $37.32 | 2020 | |
| Amarin Pharma, INC. | $30.41 | 2020 | |
| Pfizer INC. | $28.29 | 2019 | |
| Adlon Therapeutics L.P. | $14.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $14.18 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.75 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.